Genetic variation in G-protein-coupled receptors--consequences for G-protein-coupled receptors as drug targets.
G-protein-coupled receptors (GPCRs), including 'orphan' GPCRs whose natural ligands are unknown, comprise the largest membrane receptor superfamily and are the most commonly used therapeutic targets. GPCR genetic loci harbour numerous variants, such as DNA insertions or deletions and single nucleotide polymorphisms that alter GPCR expression and function, thereby contributing to inter-individual differences in disease susceptibility/progression and drug responses. In this article, the authors review examples of GPCR genetic variants that influence transcription, translation, receptor folding and expression on cell surface (by affecting receptor trafficking, dimerisation, desensitisation/downregulation), or perturb receptor function (by altering ligand binding, G-protein coupling and receptor constitutive activity). In spite of such effects, assessment for genetic variants is not currently applied to the drug development and approval process or in the clinical use of GPCR drugs. Further insights will, the authors believe, alter drug discovery/development, therapeutics and likely provide new GPCR drug targets.
Tang
Chih-Min
CM
Department of Pharmacology, University of California, San Diego, La Jolla, CA 92093-0636, USA.
Insel
Paul A
PA
D016503:Drug Delivery Systems / Q000379:methods*; D014644:Genetic Variation / Q000187:drug effects; D006801:Humans; D011110:Polymorphism, Genetic / Q000187:drug effects; D043562:Receptors, G-Protein-Coupled / Q000235:genetics* / Q000378:metabolism* / Q000502:physiology
D043562:Receptors, G-Protein-Coupled